March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Iris Neovascularisation Remodelling Under Intravitreal Vegf Suppression
Author Affiliations & Notes
  • Leonidas Zografos
    Ophthalmology, Jules-Gonin Eye Hospital, Lausanne, Switzerland
  • Aude Ambresin
    Ophthalmology, Jules Gonin Eye Hospital, Lausanne, Switzerland
    Ophthalmology, Jules-Gonin Eye Hospital, Lausanne, Switzerland
  • Footnotes
    Commercial Relationships  Leonidas Zografos, None; Aude Ambresin, None; Ann Schalenbourg, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2957. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Leonidas Zografos, Aude Ambresin, Ann SCHALENBOURG; Iris Neovascularisation Remodelling Under Intravitreal Vegf Suppression. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2957.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The aim of this prospective study was to analyse the benefit of intravitreal (IV) anti VEGF injection on iris neovascularisation (NVI) secondary to proton beam irradiation of posterior uveal malignant melanomas (MM)

Methods: : All eyes presenting secondary NVI were consecutively included. Iris fluorescein angiography (FA) was performed at baseline and at each follow up (FU) visit. Based on FA, NVI was classified as diffuse, sectorial, pupillary and tufts. The degree of dye leakage was quantified. Retreatment was applied in case of persistent leaking new vessels.

Results: : From 2006 to 2010,920 eyes received proton therapy for MM. 69 eyes presented secondary NVI. At baseline, 43% were diffuse and dye leakage was marked in 55%. Sectorial iris ischemia was present in 64% of cases. During the follow up period, the numbers of injections ranged from 1-6. Regression of NVI was observed in 68% of eyes and 67% of eyes showed reduction of dye diffusion. Over time, remodelling of the ischemic iris with progressive revascularisation occurred in 32% of eyes and 50% of eyes showed maturation of the NVI. Eye retention probability was 96%.

Conclusions: : In growth of well shaped new vessels in the ischemic zone and maturation of the NVI suggest that organised angiogenesis can occur under pharmacologically modulated VEGF expression.Anti VEGF injections is a promising therapeutic approach of NVI secondary to proton beam irradiation achieving a high rate of eye retention

Keywords: neovascularization • radiation therapy • vascular endothelial growth factor 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.